Geode Capital Management, LLC Alzamend Neuro, Inc. Transaction History

Geode Capital Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	BUY	$0.19 - $0.52 $13,746 - $37,622	72,350 Added 12.84%	636,010 $152,000
Q4 2022 Feb 13, 2023	BUY	$0.53 - $222.0 $20,092 - $8.42 Million	37,910 Added 7.21%	563,660 $318,000
Q3 2022 Nov 14, 2022	BUY	$0.88 - $178.5 $426,943 - $86.6 Million	485,163 Added 1195.37%	525,750 $625,000
Q1 2022 May 13, 2022	BUY	$0.91 - $2.23 $9,824 - $24,075	10,796 Added 36.24%	40,587 $49,000
Q4 2021 Feb 11, 2022	BUY	$1.9 - $3.08 $56,602 - $91,756	29,791 New	29,791 $56,000
Q3 2021 Nov 12, 2021	SELL	$2.28 - $7.68 $101,687 - $342,528	-44,600 Closed	0 $0
Q2 2021 Aug 13, 2021	BUY	$8.12 - $13.5 $362,151 - $602,100	44,600 New	44,600 $389,000

Ticker ALZN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 95,481,800
Market Cap $159M
Description
Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001 that is in Phase II clinical trial, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment ...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.